Clinical Trials · NCT04366726

Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)

CompletedPhase 1Abaloparatide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Radius Health, Inc.
Enrollment
22
Start date
Apr 2019
Locations
1 site, United States
Primary endpoint
Abaloparatide Maximum Plasma Concentration (Cmax) on Day 29
View Abaloparatide compound reference